Silexon Partners with Excelra, Deploying GOSTAR to Strengthen its AI-driven Drug Discovery and Biopharmaceutical Research Platform

Advertisement

HYDERABAD, India and NANJING, China, Dec. 1, 2021 /PRNewswire/ — Excelra, a leading global data & analytics provider, today announced its partnership with Silexon AI Technology, a next-generation biotech company with a scalable AI/ML (Artificial Intelligence and Machine Learning) platform for drug discovery and biopharmaceutical research.

Excelra Logo

Under the agreement, Excelra will provide ADMET and Binding Assays datasets from its GOSTAR database to Silexon. GOSTAR provides comprehensive information encompassing over 8 million compounds and contains more than 28 million SAR associated data points. The well-structured relational database can be utilized for diverse applications across different phases of drug discovery and development and aids in target validation, hit identification, early lead Identification, and optimization.

Silexon’s AI/ML platform uses both high-quality, real-world biological data and outstanding machine learning capabilities to aid in de novo drug design, drug discovery, and biopharmaceutical research through its disruptive predictive tools that help streamline the discovery and design process, thus shortening the time to market for new life-saving drugs. Silexon focuses on innovative biomedicines with unique target product profiles for undruggable, difficult-to-drug, and novel targets in multiple therapeutic areas.

Anandbir Singh Brar, CEO of Excelra, said, “We are excited that GOSTAR has become the gold standard dataset for Biopharma and AI/ML companies. Our partnership with Silexon underscores GOSTAR’s ability to provide large, normalized, quality-controlled datasets that empower a wide range of predictive models. We are delighted to partner with Silexon and to be part of their journey in developing the AI4D platform for drug discovery.”

Hainian ZENG, CEO of Silexon, said, “We look forward to combining the well-annotated GOSTAR data with data accumulated and generated by Silexon’s proprietary AI/ML models and wet-lab experiments. Using our AI/ML platform, we aim to address bottlenecks in drug discovery and biopharmaceutical research to ultimately deliver innovative therapeutic candidates with higher overall success rates. Our preliminary assessment gives us the confidence that GOSTAR’s database would be an important addition to our current training dataset for next-generation modeling.”

About Silexon:

Silexon is an emerging AI-empowered technology company that aims to create an open AI platform for strategic collaboration to facilitate data-driven biopharma research, empower drug R&D processes, and ultimately provide patients with greater access to innovative drugs for their unmet medical needs. Silexon stands for the integration of Silicon and Exon, and hence machine plus life. To know more, visit http://www.silexon.tech/

About Excelra:

Excelra’s data and analytics solutions empower innovation in life sciences from molecule to market. The Excelra Edge comes from a seamless amalgamation of proprietary data assets, domain expertise, and data sciences to accelerate drug discovery and development.

Excelra’s Global Online Structure Activity Relationship Database (GOSTAR) is the largest repository for structured SAR content. Available as a one-stop data source, GOSTAR allows researchers to thoroughly explore the known chemical space around a target of interest. The database is manually curated by scientific teams who excerpt and enrich datasets from functional assays, in vitro, and in vivo studies. A variety of small molecule activities encompassing SAR, physicochemical, metabolic, ADME, and toxicological profiles are captured in GOSTAR.

To know more, visit: https://www.gostardb.com/

Media Contact:

Jigesh Shah – Director Marketing

Email:  [email protected]

Logo: https://www.businessupturn.com/wp-content/uploads/2021/12/silexon-partners-with-excelra-deploying-gostar-to-strengthen-its-ai-driven-drug-discovery-and-biopharmaceutical-research-platform-1.jpg

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.

Subscribe to our newsletter
Subscribe to our newsletter
Sign up here to get the latest news delivered directly to your inbox.
You can unsubscribe at any time